HOOKIPA Pharma Inc. (HOOK)
| Market Cap | 150.06M |
| Revenue (ttm) | 19.88M |
| Net Income (ttm) | -60.45M |
| Shares Out | 29.81M |
| EPS (ttm) | -2.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 146,096 |
| Open | 5.14 |
| Previous Close | 5.17 |
| Day's Range | 4.90 - 5.15 |
| 52-Week Range | 4.90 - 20.00 |
| Beta | 1.15 |
| Analysts | Buy |
| Price Target | 22.88 (+355.8%) |
| Est. Earnings Date | Nov 11, 2021 |
About HOOK
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cance...
Financial Performance
In 2020, HOOKIPA Pharma's revenue was $19.58 million, an increase of 63.99% compared to the previous year's $11.94 million. Losses were -$44.08 million, 2.43% more than in 2019.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for HOOKIPA Pharma stock is "Buy." The 12-month stock price forecast is 22.88, which is an increase of 355.78% from the latest price.
News
HOOKIPA announces publication on the benefits of its novel arenaviral immunotherapeutics in cancer in Frontiers in On...
NEW YORK and VIENNA, Austria., Oct. 14, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus...
HOOKIPA (HOOK), Merck Collaborate to Treat Head & Neck Cancers
HOOKIPA (HOOK) collaborates with Merck (MRK) to evaluate the combination of its immunotherapy program, HB-200, with Merck's Keytruda for advanced head and neck squamous cell carcinoma.
Hookipa Pharma, Merck Team Up For Phase 2 Head & Neck Cancer Trial
Hookipa Pharma Inc (NASDAQ: HOOK) has entered into a clinical collaboration and supply agreement with Merck & Co Inc (NYSE: MRK). The collaboration will evaluate the combination of HB-200 and Keytruda (...
HOOKIPA announces clinical collaboration with Merck & Co., Inc., Kenilworth, NJ., USA to evaluate HB-200 in combinati...
NEW YORK and VIENNA, Austria, Sept. 15, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus...
HOOKIPA Pharma to Participate in Upcoming Investor Conferences in September
NEW YORK and VIENNA, Austria, Sept. 07, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus...
HOOKIPA Pharma Inc. (HOOK) Reports Q2 Loss, Misses Revenue Estimates
HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of 0.00% and -1.32%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Recap: HOOKIPA Pharma Q2 Earnings
Shares of HOOKIPA Pharma (NASDAQ:HOOK) moved higher by 3.3% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 85.71% over the past year to ($0.5...
Analysts Estimate HOOKIPA Pharma Inc. (HOOK) to Report a Decline in Earnings: What to Look Out for
HOOKIPA Pharma Inc. (HOOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pre-clinical data on HOOKIPA's arenaviral immunotherapeutic in melanoma published in Nature Communications
NEW YORK and VIENNA, Austria, Aug. 05, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus ...
HOOKIPA Pharma to Participate in Upcoming Investor Conferences in June
NEW YORK and VIENNA, Austria, June 10, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus ...
Hookipa Pharma's Cancer Immunotherapy Shows T-Cell Response, Interim Efficacy in Pretreated HPV16+ Cancer Settings
Hookipa Pharma Inc (NASDAQ: HOOK) reported positive Phase 1 data from its ongoing Phase 1/2 study evaluating HB-200 to treat advanced Human Papillomavirus 16-positive (HPV16+) cancers. Data were present...
HOOKIPA Phase 1 HB-200 data show unprecedented T cell response, favorable tolerability, and preliminary efficacy as m...
NEW YORK and VIENNA, Austria, June 07, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus ...
HOOKIPA Pharma Inc. (HOOK) Soars 7.9%: Is Further Upside Left in the Stock?
HOOKIPA Pharma Inc. (HOOK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price incr...
HOOKIPA Pharma Inc. (HOOK) Reports Q1 Loss, Tops Revenue Estimates
HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of 0.00% and 38.30%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
HOOKIPA Pharma: Q1 Earnings Insights
Shares of HOOKIPA Pharma (NASDAQ:HOOK) fell 6.1% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 23.26% year over year to ($0.53), which were in li...
HOOKIPA Pharma Reports First Quarter 2021 Financial Results and Recent Highlights
NEW YORK and VIENNA, Austria, May 12, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus p...
Is a Surprise Coming for HOOKIPA (HOOK) This Earnings Season?
HOOKIPA (HOOK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
HOOKIPA Pharma Inc. (HOOK) Expected to Beat Earnings Estimates: Should You Buy?
HOOKIPA Pharma Inc. (HOOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HOOKIPA Pharma to Participate in Upcoming Investor Conferences in May
NEW YORK and VIENNA, Austria, April 29, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus...
HOOKIPA Pharma to Present at Kempen Life Science Conference
NEW YORK and VIENNA, Austria, April 14, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus...
HOOKIPA announces positive preliminary Phase 1 immunogenicity data for its immunotherapy candidates to treat advanced...
NEW YORK and VIENNA, Austria, April 10, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus...
HOOKIPA Pharma Inc. (HOOK) Reports Q4 Loss, Tops Revenue Estimates
HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of 17.86% and 0.98%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
HOOKIPA Pharma: Q4 Earnings Insights
Shares of HOOKIPA Pharma (NASDAQ:HOOK) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share decreased 15.00% over the past year to ($0.46), which beat the esti...
Analysts Estimate HOOKIPA Pharma Inc. (HOOK) to Report a Decline in Earnings: What to Look Out for
HOOKIPA Pharma Inc. (HOOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HOOKIPA Pharma (HOOK) in Focus: Stock Moves 8.4% Higher
HOOKIPA Pharma (HOOK) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.